Filter Results
:
(213)
Show Results For
- All HBS Web (213)
- Faculty Publications (140)
Show Results For
- All HBS Web (213)
- Faculty Publications (140)
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Disorders;
Health Testing and Trials;
Power and Influence;
Competitive Strategy;
Pharmaceutical Industry;
European Union;
Germany;
United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.
- April 1989 (Revised January 1994)
- Case
Novo Industri
By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an...
View Details
Keywords:
Change;
Global Strategy;
Industry Structures;
Alliances;
Competitive Strategy;
Health Disorders;
Pharmaceutical Industry
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
- 26 Mar 2013
- News
Ex-Washington Governor Dies at 76
- 21 Mar 2012
- News
O'Donnells donate $30 million to Harvard
- 01 Jun 2002
- News
Up to the Challenge: Martin Gonzalez - Quiet Courage
Photography by Robert Schoen If I take one overall impression away from HBS, it's that everyone here has a powerful story to tell,” says Martin Gonzalez, a lanky Chilean whose own life story took a dramatic turn during his first year at Soldiers Field. A former...
View Details
- August 2010 (Revised January 2013)
- Case
Avi Kremer
By: Joshua D. Margolis and Mark Wetzel
If you were diagnosed with a terminal illness, how would you respond and what would you do with your remaining time? Avi Kremer contemplates four options for how to devote himself 18 months after being diagnosed with ALS. His experience thus far and the choices he...
View Details
Keywords:
Entrepreneurship;
Values and Beliefs;
Health Disorders;
Leadership Development;
Personal Development and Career;
Social Enterprise;
Personal Characteristics
Margolis, Joshua D., and Mark Wetzel. "Avi Kremer." Harvard Business School Case 411-022, August 2010. (Revised January 2013.)
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Nonprofit Organizations;
Health Disorders;
Health Care and Treatment;
Resource Allocation;
Global Range;
Decisions;
Investment Funds
Rangan, V. Kasturi, and Courtney Han. "The END Fund: To Eliminate Neglected Tropical Diseases." Harvard Business School Case 523-063, January 2023.
- 01 Dec 2013
- News
Faster, Bigger, Stronger: Supersizing the NFL
defense internally and in the public spotlight. Along with reports of players' pharmacological and off-field transgressions (behaviors also found in other professional sports leagues), the NFL has had to address new medical research into football's deleterious View Details
- June 2011
- Teaching Note
PatientsLikeMe: An Online Community of Patients (TN)
By: Sunil Gupta and Jason Riis
Teaching Note for 511093.
View Details
- January 2023
- Supplement
The END Fund (B)
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Health Disorders;
Investment Funds;
Global Range;
Nonprofit Organizations;
Resource Allocation;
Decisions;
Health Care and Treatment;
Mission and Purpose
Rangan, V. Kasturi, and Courtney Han. "The END Fund (B)." Harvard Business School Supplement 523-064, January 2023.
- Article
Putting Patients First: Social Marketing Strategies for Treating HIV in Developing Nations
By: Zoe Chance and Rohit Deshpandé
It is more than mere coincidence that the highest rates of HIV occur in the world's poorest countries. Of the over 40 million people currently living with HIV, 95 percent are in the developing world. The first part of this paper explores the economics of HIV and...
View Details
Keywords:
Health Disorders;
Developing Countries and Economies;
Poverty;
Health Care and Treatment;
Social Marketing;
Perspective;
Customer Focus and Relationships;
Profit;
Africa;
Asia;
South America
Chance, Zoe, and Rohit Deshpandé. "Putting Patients First: Social Marketing Strategies for Treating HIV in Developing Nations." Special Issue on Metric and Interpretive Explorations of Macromarketing. Journal of Macromarketing 29, no. 3 (September 2009).
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (A)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Disorders;
Product Launch;
Negotiation Process;
Business and Government Relations;
Safety;
Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (A)." Harvard Business School Case 909-001, August 2008. (Revised September 2008.)
- September 2009 (Revised August 2012)
- Case
Novasys Medical
By: Richard G. Hamermesh and Lauren Barley
Novasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the...
View Details
Keywords:
Entrepreneurship;
Governing Rules, Regulations, and Reforms;
Policy;
Health Care and Treatment;
Health Disorders;
Product Development;
Business and Government Relations;
Medical Devices and Supplies Industry;
United States
Hamermesh, Richard G., and Lauren Barley. "Novasys Medical." Harvard Business School Case 810-027, September 2009. (Revised August 2012.)
- 01 Sep 2010
- News
RX for Change
employs 9,000 people and ranks as Georgia’s largest, most comprehensive health system. Under consideration this day is a proposal to add specialists — known as neurohospitalists — to manage care for patients with View Details
- December 1993 (Revised November 2009)
- Case
Manville Corporation Fiber Glass Group (A)
By: Lynn S. Paine and Sarah Gant
Manville Corp.'s senior managers must decide how to respond to a new scientific study suggesting that fiberglass, the source of 75% of the company's profits, may be another asbestos and must act under conditions of great uncertainty. In particular, when should a...
View Details
Keywords:
Communication Strategy;
Decision Choices and Conditions;
Ethics;
Health Disorders;
Risk Management;
Marketing Communications;
Product;
Corporate Social Responsibility and Impact;
Safety;
Consumer Products Industry;
Industrial Products Industry
Paine, Lynn S., and Sarah Gant. "Manville Corporation Fiber Glass Group (A)." Harvard Business School Case 394-117, December 1993. (Revised November 2009.)
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process....
View Details
Keywords:
Drug Development;
Drug Discovery;
Drug Trials;
Pharmaceutical Companies;
Pharmaceutical Company;
Pharmaceuticals;
Therapeutics;
Biologics;
Biotech;
Biotechnology;
Biopharmacy Company;
Biochemistry;
Technology Commercialization;
Technology Companies;
Drug Testing;
Startup;
Start-up;
Startups;
Start-ups;
Startup Financing;
Strategic Decision Making;
Strategic Decisions;
Strategic Evolution;
FDA;
Food And Drug Administration;
Clinical Trials;
Disease Management;
Market Attractiveness;
Market Entry;
Market Opportunities;
Health Disorders;
Technological Innovation;
Information Technology;
Commercialization;
Business Startups;
Finance;
Decision Making;
Strategy;
Market Entry and Exit;
Opportunities;
Pharmaceutical Industry;
Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
- December 2012 (Revised November 2014)
- Case
W.R. Grace & Co.: Dealing with Asbestos Torts
By: Stuart C. Gilson and Sarah L. Abbott
A manufacturer of building products and specialty chemicals, W. R. Grace & Co. filed for Chapter 11 bankruptcy in 2001 in response to a flood of lawsuits alleging that its products contained asbestos, and had caused hundreds of thousands of people to contract...
View Details
Keywords:
Bankruptcy Reorganization;
Business Failures;
Environmental Regulations;
Class Action Lawsuits;
Natural Environment;
Valuation;
Health Disorders;
Capital Structure;
Restructuring;
Lawsuits and Litigation;
Chemicals;
Crisis Management;
Insolvency and Bankruptcy;
Legal Liability;
Construction Industry;
Chemical Industry;
United States
Gilson, Stuart C., and Sarah L. Abbott. "W.R. Grace & Co.: Dealing with Asbestos Torts." Harvard Business School Case 213-046, December 2012. (Revised November 2014.)
- 01 Nov 2012
- News
First and Goal
Swearengin: Leadership with the game on the line. Photo courtesy Julian Swearengin Julian Swearengin (MBA 2003) has loved football ever since he began playing the game at age 5. “Growing up poor and on welfare in Detroit, the classroom and the field were the only two...
View Details
- 01 Dec 2010
- News
This Is What I Do
Katie Hood: Fast Forward Hood Hood and Fox In the hit movie Back to the Future, actor Michael J. Fox plays Marty McFly, a teenager in a hurry. Accidentally sent backward through time, Marty encounters a slew of nasty complications. (One of his main concerns is eluding...
View Details
- 01 Dec 2011
- News
Making the Case for Leadership
Angeles–based dialysis provider TRC. Thiry (MBA 1983) had just completed a difficult, ultimately unsuccessful term as CEO of another health care organization. After that experience, he pledged to join his wife, Denise O’Leary (also MBA...
View Details
Keywords:
Garry Emmons;Julia Hanna;Roger Thompson;
Performing Arts, Spectator Sports, and Related Industries;
Arts, Entertainment;
National Security and International Affairs;
Government;
Health, Social Assistance;
Data Processing, Hosting, and Related Services;
Information;
Electrical Equipment, Appliance, and Component Manufacturing;
Manufacturing;
Food Manufacturing;
Manufacturing;
Nonmetallic Mineral Product Manufacturing;
Manufacturing;
Management, Scientific, and Technical Consulting Services;
Professional Services